Scientometric study of global mucormycosis (black fungus) research by L R, Rahul  & Nishy, P 
 
 
Annals of Library and Information Studies 





Scientometric study of global mucormycosis (black fungus) research 
Rahul LRa and Nishy Pb 
aSenior Technical Officer, CSIR–National Institute for Interdisciplinary Science and Technology (NIIST),  
Thiruvananthapuram, Kerala, India  
bCorresponding author: Chief Scientist, CSIR–National Institute for Interdisciplinary Science and Technology (NIIST), 
Thiruvananthapuram, Kerala, India, Email: nishy@niist.res.in 
Received: 02 June 2021; revised: 15 November 2021; accepted: 23 November 2021 
Mucormycosis, a rare infection, caught the attention during the COVID-19 pandemic. Many COVID-19 and post-
COVID-19 patients were infected by the black fungus. This study presents a scientometric review of 6661 research articles 
related to mucormycosis published from 1947 to 2021 indexed in Scopus and Web of Science. The study analyses the 
publications quantitatively in terms of growth, collaboration, countries, institutions, journals, keywords, and impact 
(citation) using the Bib-Excel and visualized in the VOSviewer tool. The highest number of publications on mucormycosis 
research is from the USA, followed by India, China, Germany, France, and Japan. Most of the research collaborations are 
among institutions in Europe and the USA. The University of Texas-USA is the most productive institute followed by 
PGIMER-India. However, the papers from Indian institutes have a significantly lower citation impact than those from the 
other leading countries. Since most international research is restricted among a few institutes, the international collaboration 
in mucormycosis research needs to be enhanced for high-quality research. The analysis of author-assigned keywords showed 
that the studies on the drug isavuconazole to treat mucormycosis are lesser than other major drugs. The research on surgical 
management of mucormycosis can be improved. Research on the diagnosis methods for mucormycosis and the genetic 
studies on the causative fungi of the order Mucorales are to be promoted. There are a few studies on Rhizomucor, 
Lichtheimia, Cunninghamella, Saksenaea, and Apophysomyces, among the several fungi genera that cause mucormycosis. 
Since mucormycosis is becoming more prevalent and severely affecting a larger population as a post-COVID syndrome, 
research in this area should be strengthened and new drugs should be explored. 
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Introduction 
Mucormycosis (sometimes called black fungus) is 
a fungal infection caused by fungi in the order 
Mucorales. The major predisposing conditions are 
uncontrolled diabetes, neutropenia, malignancies, 
receipt of a transplant, and traumatic injury; and the 
use of systemic glucocorticoids for the treatment of 
COVID-19 may also lead to secondary bacterial or 
fungal infections, including mucormycosis1-4. A total 
of 11 genera and ~27 species under the order 
Mucorales cause mucormycosis. Rhizopus, 
Lichtheimia, and Mucor represent the most common 
fungi genera associated with human disease5. Types 
of mucormycosis in the human body include rhino-
orbital-cerebral, pulmonary, gastrointestinal, 
cutaneous, renal, disseminated, and central nervous 
system mucormycosis6. The prognosis of 
mucormycosis is poor, with an approximate mortality 
rate of 54%; the mortality rate depends upon the 
underlying patient condition, type of fungus, and part 
of the body affected7.  
Though the exact burden of mucormycosis is 
unknown, studies suggest that the cases are rising 
globally. The rise is very high in India and China 
among patients with uncontrolled diabetes mellitus8. 
Blindness, clots in brain or lung blood vessels, and 
partial loss of neurological function are the major 
complications of mucormycosis9. Mucormycosis is 
usually rare, affecting fewer than 2 people per million 
in San Francisco each year. However, it is currently 
80 times more common in India10.  
During the COVID-19 pandemic in India, the 
disease became a major public health concern. As of 
July 2021, approximately 45,374 cases of 
mucormycosis were reported from India, and more 
than 4,300 people have died11. Mucormycosis rates in 
India were predicted to be 70 times greater than the 
rest of the world even before the COVID-19 
epidemic12. The cases of mucormycosis in India may 
be underreported due to the difficulties in diagnosis in 
rural areas, and a number of recovered patients after 
treatment appeared to be suffering from a relapse11. 




Mucormycosis has a higher morbidity rate than 
other invasive fungal infections like aspergillosis. 
More advances in understanding host defence, the 
invention of advanced early diagnostic systems, and 
the development of new superior therapeutic methods 
may help to improve the prognosis of the disease13. 
Scientometrics was first defined by Nalimov 
(1971) as developing “the quantitative methods of the 
research on the development of science as an 
informational process”14. Scientometrics helps to 
measure and analyse academic publications. The 
measuring of the influence of research papers and 
academic journals, as well as the comprehension of 
scientific citations and the application of such 
measurements in policy and management contexts, 
are the major applications of scientometrics15. 
This scientometric study on mucormycosis may aid 
researchers in exploring less focused subject areas, 
identify the researchers, institutes, or countries for 
research collaboration, and select journals for 
publishing the output. This study may also assist the 
policymakers and governments to understand the 
current research scenario and make better-informed 
decisions and benefits the funding agencies for better 
allocation of their funds to focus on the research gaps. 
 
Review of literature 
One scientometric study has been published on 
mucormycosis16. The study attempted to illustrate the 
mucormycosis research with bibliometric software 
“Biblioshiny” with the data retrieved from WoS. The 
results indicate that the research collaboration 
between institutes was fewer.  
Kalra et al., studied 616 papers from WoS on 
COVID-19 related research on ophthalmology. India, 
USA, UK, and China had published most, and they 
classified Ranibizumab and keratitis as emerging or 
declining research areas17. A scientometric evaluation 
of coronavirus research published during 1900-2020 
was conducted. More than 89 percent of papers came 
from the top twenty nations, indicating a lack of 
international cooperation. The majority of networking 
was among wealthy countries, implying that low and 
middle-income countries require more collaboration18. 
Global COVID-19 research based on the Dimensions 
database was examined. China was found to be the 
highly cited country, and the majority of productive 
institutes were from China. The most collaborative 
studies were conducted by Fudan University19.  
The United States was leading international 
collaborative efforts, and the countries severely 
affected by COVID-19 accelerated their research on 
COVID-1920. 
Ramírez-Malule H et al.,21 analysed 227 Scopus 
indexed papers on Candida auris published during 
2009-2018. The leading publishing countries were the 
USA, India, and the UK. The authors also listed the 
possible drugs used by researchers for facing the 
emerging antifungal resistance to Candida auris. 
Yujieet al.,22 examined 1906 records indexed in Web 
of Science (WoS) on fungal keratitis published during 
1959-2019 and explained the current status, trends, 
and hotspots of the fungal keratitis research field. 
Singh P et al.,23 analysed 5358 records on Fusarium 
oxysporum published during 2009-2018 using WoS. 
The most productive country was China, followed by 
India, and India topped the list when analysing 
citations received. They also observed that many of 
the Fusarium oxysporum fungi species were not 
getting sufficient research attention. 
 Joshi K et al.,24 examined global scientific 
productivity on forest fungi. The data published 
during 1987-2008 were extracted from WoS. The 
results indicated that the worldwide research on forest 
fungi is improving. The USA published most, and 
China had the highest growth rate in publications. A 
bibliometric study on oncolytic virus research for 
cancer therapy was conducted25. The researchers from 
the USA published most followed by China, and the 
most prominent institute was Mayo clinic-USA. The 
selected studies indicated that adenovirus, herpes 
simplex virus, reovirus, and Newcastle disease virus 
had shown potent anti-cancer activity. 
As the number of cases of mucormycosis rises 
during the COVID-19 period, this study will assist in 
understanding the research gaps to be addressed. 
 
Objective of the study 
• To examine and analyse research output on 
mucormycosis using various scientometric 
indicators, examine the citation pattern, identify 
the journals that publish mucormycosis research, 
review international and institutional 
collaboration, and analyse the keywords used by 
researchers to explore the focal areas of research 




Two major citation databases, Web of Science 
(WoS) and Scopus, were selected to download the 
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had a significant research performance in the first half 
of 2021, which might be attributed to the impact of a 
higher number of mucormycosis patients in India 
linked to COVID-19. 
Figure 2 depicts the progress of mucormycosis 
research in the top countries over the decades. More 
than 110 countries have been contributed to 
mucormycosis research. The top twenty countries 
have been published for 78.4% of the total 
publications and received 86.2% citations. The data 
depicts that the research on mucormycosis is active 
only in a few countries, so involvement of other 
countries in research on mucormycosis is needed for 
tackling this fatal infection. 
The impact of the research is counted in citations 
received; amongst the top twenty countries, 
publications from Canada (53.58) have obtained the 
highest CPP, followed by the Netherlands (46.71) and 
Austria (40.07). All the Asian countries in the top 
twenty list had a comparatively lower CPP. Except for 
Spain (22.53), all European countries, Australia, and 
the USA received a CPP of more than twenty-five. 
Among the top ten countries, the highest CPP was for 
papers from the UK (38.28), followed by the USA 
(32.66) and Germany (32.55). 
 
Impact of research output of prolific countries 
The i10 index measures the number of publications 
with at least ten citations. For seven countries 
(Australia, Greece, USA, Netherlands, UK, Canada, 
and Brazil,) more than 50% of their publications 
received ten or more citations. The USA, India, 
Table 1 — Growth of research over the years 














Before 1971 194 5023 194 5023 25.89 8  
1971-80 215 4997 409 10020 24.50 22 10.825 
1981-90 553 10240 962 20260 21.06 55 157.209 
1991-2000 908 20902 1870 41162 22.01 91 64.195 
2001-10 1654 46167 3524 87329 24.78 165 82.159 
2010-20 2924 30562 6448 117891 18.28 292 76.784 
2021 (As of July) 213 113 6661 118004 17.72 213  
 
 
Table 2 — Country-wise distribution of publications 
Sl No. Country Publications (P) Citations ( C )CPP = C/P










1 USA 1823 59540 32.66 466 1206 116.54 96.26 -20 964 
2 India 748 7167 9.58 75 622 45.71 120.99 75 176 
3 P R China 401 6964 17.37 5 362 5.68 131.35 126 128 
4 Germany 366 11912 32.55 39 305 48.58 121.25 73 166 
5 France 325 9437 29.04 57 257 79.96 115.06 35 136 
6 Japan  303 6202 20.47 90 199 135.42 95.56 -40 93 
7 Spain 299 6736 22.53 81 209 123.51 101.70 -22 119 
8 U K 212 8116 38.28 55 143 118.28 98.14 -20 108 
9 Italy 178 4974 27.94 28 142 71.72 116.07 44 69 
10 Australia 159 4070 25.60 42 113 120.43 103.41 -17 96 
11 Brazil 152 3762 24.75 28 117 83.99 112.00 28 76 
12 Iran 135 1500 11.11 2 125 6.75 134.72 128 29 
13 Canada 128 6858 53.58 26 96 92.61 109.13 17 65 
14 Turkey 128 1852 14.47 12 113 42.74 128.45 86 36 
15 Greece 126 4373 34.71 6 117 21.71 135.11 113 70 
16 S. Korea 120 1672 13.93 13 103 49.39 124.89 75 37 
17 Switzerland 107 3150 29.44 14 81 59.65 110.15 50 48 
18 Austria 106 4247 40.07 7 93 30.11 127.66 98 50 
19 Mexico 101 1322 13.09 8 84 36.11 121.01 85 27 
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between the citations received by the publications on 
mucormycosis and the IF and Citescore of the 
journals that published them. However, in the case of 
some journals such as Clinical Infectious Diseases, 
Clinical Microbiology and Infection, and 
Antimicrobial Agents and Chemotherapy, the papers 
published on mucormycosis have received more 
citations than the average citations received for the 
papers on other subject areas. It can also be observed 
from the figures that the publications on 
mucormycosis in the journals, Journal of Fungi, 
Chest, Medical Mycology Case Reports and Journal 
De Mycologie Medicale have received citations that is 
significantly lower than the average citations received 
for papers in the same journals on other subject areas, 
while considering the IF and Citescore of journals. 
 
Impact of research output of prolific institutions 
More than 4000 institutions were published on 
mucormycosis research; however, the research is 
concentrated in a few institutions. Only twenty-eight 
institutions in the world have published more than 
thirty papers on mucormycosis. Table 4 lists the 
institutes that published more than forty papers on 
mucormycosis. The top nineteen institutes contributed 
20% of the global publications and acquired 63% of 
the total citations. This data suggests that a few 
institutes published the top-cited publications. Hence 
more institutes need to collaborate with prominent 
institutes for conducting and publishing high-quality 
research. The University of Texas-USA has published 
the most number of papers and secured 11.65% of the 
global citations with a CPP of 62.22. It was the only 
institute that had an i10 index of more than hundred 
(143). The second top institute was PGIMER-India, 
which published 134 papers with a relatively lower 
CPP of 21.12. 
 Apart from the four institutes each from the USA 
and Europe, only two institutes from other continents 
were involved in the top ten most productive 
institutes. They were PGIMER and AIIMS, both from 
India. However, the publications from these institutes 
cited significantly less than that of the other top 
institutes. The publications from AIIMS-India had 
received the lowest CPP of 8.26, and only 29% of the 
publications from AIIMS-India were received more 
than ten citations. The University of Pennsylvania-
USA has obtained the highest CPP (142.31) among 
the top institutions, followed by Duke University-
USA (103.56). Almost one-third of the publications 











i10 as  
% P 
NCP as  
% P 






1 Mycoses 273 2880 100 91 36.63 33.33 10.55 3.575 6.1 
2 Medical Mycology 97 1499 47 17 48.45 17.53 15.45 2.822 5.7 
3 Mycopathologia 96 1010 29 6 30.21 6.25 10.52 2.452 5.0 
4 Clinical Infectious 
Diseases 
96 12110 83 6 86.46 6.25 126.15 8.313 13.2 
5 Medical Mycology 
Case Reports 
59 190 5 12 8.47 20.34 3.22 - 1.8 
6 Journal De Mycologie 
Medicale 
59 238 6 12 10.17 20.34 4.03 1.56 4.0 
7 Journal of Clinical 
Microbiology 
57 2264 50 3 87.72 5.26 39.72 5.897 9.4 
8 Mycologia 54 2217 38 0 70.37 0.00 41.06 2.149 3.9 
9 Clinical Microbiology 
And Infection 
54 3104 51 1 94.44 1.85 57.48 7.117 11.7 
10 Journal of Fungi 47 334 11 11 23.40 23.40 7.11 4.621 5.5 
11 Chest 47 582 18 24 38.30 51.06 12.38 8.308 10.3 
12 Antimicrobial Agents 
And Chemotherapy 
47 2517 35 1 74.47 2.13 53.55 4.904 9.1 
13 Transplant Infectious 
Disease 
44 878 18 6 40.91 13.64 19.95 2.071 3.1 
14 Indian Journal of 
Otolaryngology And 
Head & Neck Surgery 
41 121 1 10 2.44 24.39 2.95 - 0.6 
15 Current Fungal 
Infection Reports 
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conducted with international cooperation. Those 
papers had received two-fold more CPP (38.29)  
than the papers with authors from single countries. 
Figure 5 shows a collaborative diagram with countries 
as nodes and links as the number of collaborative 
publications between countries. The size of the nodes 
is proportional to the publications from the country. 
The thickness of the connecting diagram is 
proportional to the collaborative publications between 
the countries. 
The highest number of collaborative publications is 
from the USA with Germany (61), followed by 
Austria with Germany (45). As visible in the green 
cluster, authors from the USA collaborated with a 
Table 4 — Most prolific institutes 
 Institutions Publications 
(P) 
Citations 
( C ) 






% of  
P 
1 Univ. Texas-USA 221 13750 62.22 143 64.71 31 14.03 
2 Postgrad. Inst. Med. Educ. & Res. PGIMER-India 134 2830 21.12 57 42.54 17 12.69 
3 Duke Univ.-USA 94 9735 103.56 69 73.40 10 10.64 
4 Univ. Calif. Los Angeles UCLA-USA 89 5128 57.62 68 76.40 4 4.49 
5 CNRS, Inst. Pasteur-France 77 3233 41.99 51 66.23 7 9.09 
6 Med. Univ. Innsbruck-Austria 69 2789 40.42 34 49.28 21 30.43 
7 All India Inst. of Med. Sciences-India 69 570 8.26 20 28.99 16 23.19 
8 Univ. Cologne-Germany 64 1520 23.75 26 40.63 20 31.25 
9 Hop Necker Enfants Malad-France 58 2853 49.19 34 58.62 8 13.79 
10 Cornell Univ.-USA 57 3252 57.05 33 57.89 3 5.26 
11 Mayo Clinic-USA 55 3536 64.29 32 58.18 10 18.18 
12 Univ. Athens-Greece 53 3097 58.43 38 71.70 9 16.98 
13 Aristotle Univ. Thessaloniki-Greece 47 2320 49.36 27 57.45 8 17.02 
14 CDCP, Natl. Ctr. Infect. Dis.-USA 46 3565 77.50 37 80.43 3 6.52 
15 Univ. Pittsburgh-USA 44 2219 50.43 26 59.09 10 22.73 
16 Univ. Manchester-United Kingdom 44 1875 42.61 27 61.36 6 13.64 
17 Univ. Penn.-USA 42 5977 142.31 27 64.29 5 11.90 
18 Chinese Acad. Sci.-Peoples R China 42 2895 68.93 26 61.90 1 2.38 
19 Univ. Calif. Los Angeles-USA 41 2992 72.98 35 85.37 3 7.32 
 
     
Fig. 5 — International collaboration 
 
Austria 




number of countries from all continents except Africa. 
Authors from the USA had published more than thirty 
papers with Germany (61), Canada (41), France (39), 
Spain (38), China (36), and Greece (34).  
The blue cluster is the collaboration between 
European countries; Germany had co-operative 
research with the USA (61), Austria (45), France (37), 
Switzerland (31), Netherlands (29), and the UK (25). 
The Asian countries that were involved in publishing 
a minimum of fifteen papers with collaboration  
were China (36 papers with the USA), India  
(27 papers with the USA), and Israel (16 papers  
with the USA). The only country involved from  
South America was Brazil (22 papers with the USA). 
Australia published twenty-two papers with the  
USA and fifteen with Germany. Researchers from the 
USA were found to be more connected with 
researchers from developing countries like China, 
India, and Brazil.  
Only four countries, China, India, Israel, and 
Brazil, published at least fifteen publications with 
international collaboration, aside from the European 
countries, the United States, Canada, and Australia. 
Only 10% of the publications on mucormycosis were 
published with international collaboration, and the 
countries involved were also limited. Asian and 
African countries need to involve in more research 
with international cooperation. 
 
Institutional collaboration 
Figure 6 represents the institutional collaboration 
links. While analysing the institutional collaboration, 
the strongest link was between the French institutes, 
CNRS Institut Pasteur, and Necker–Enfants Malades 
Hospital (39), followed by the US institutes, 
University of California, and University of Texas 
(32). The University of Cologne-Germany has 
published more than ten papers in partnership with 
three international institutes. The strongest links were 
between institutes from the USA, Germany, France, 
Austria, and Greece. PGIMER is the Indian institute 
that was actively collaborated with other institutes. 
PGIMER-India collaboratively published six papers 
each with the Medical University of Innsbruck-
Austria and Canisius Wilhelmina Hospital-
Netherlands, as well as five papers each with AIIMS-
India, University of Pittsburgh-USA and Enfants 
Malades Hospital-France.  
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(100), and the fungi class, Zygomyctetes (154). Other 
fungi genera discussed were Absidia (48), 
Cunninghamella (44), Candida (39), Rhizomucor 
(38), Lichthemia (29), Apophysomyces (27), 
Saksenaea (27), and Fusarium (27). The genera most 
commonly implicated in human mucormycosis 
infections are Rhizopus, Mucor, Rhizomucor, 
Lichtheimia, Cunninghamella, Saksenaea, and 
Apophysomyces40. The studies on the genera 
Rhizomucor, Lichtheimia, Cunninghamella, 
Saksenaea, and Apophysomyces need to be enhanced. 
Since the genus, Cunninghamella is associated 
with higher mortality rates1, more research on 
Cunninghamella is expected. 
 
Risk factors 
Uncontrolled diabetes mellitus, corticosteroid 
therapy, organ or bone marrow transplantation, 
neutropenia, trauma and burns, malignant 
hematologic conditions, and deferoxamine therapy in 
hemodialysis patients are some of the important risk 
factors for mucormycosis41-43. 
Diabetes (299) was the most discussed risk factor 
related to mucormycosis; of that, 38 papers were on 
diabetic ketoacidosis. There were 263 publications 
related to the immune system. The immuno–
compromised host was discussed in 102, immuno–
competent in 85, immunosuppression in 66, and 
immunodeficiency in 10 publications. Kidney 
transplantation was a topic in 61 publications, 
followed by stem cell transplantation (52) and liver 
transplantation (13). 
 Hematologic malignancies (including leukemia 
and lymphoma) were discussed in 141 publications 
and chemotherapy in 10. Neutropenia was studied in 
49, and trauma was in 28 papers. Research related to 
iron was seen only in 24 publications, including 11 on 
deferoxamine. The human immunodeficiency virus 
was a keyword in 28 publications. 
COVID-19 was a keyword in 25 publications. 
 
Other keywords  
Epidemiology was involved in 68, prophylaxis in 
40, mortality in 28, and prognosis in 14 publications. 
Fungal sinusitis was a keyword in 98 papers, orbital 
apex syndrome in 22, necrotizing fasciitis in 19, and 
brain abscess in 15 papers. There were only 15 studies 
related to pharmacokinetics.  
 
Conclusion 
This study provides a scientometric review of the 
present body of literature focusing on mucormycosis 
research which is slowly increasing. The highest 
number of research output is from the USA, followed 
by India and China. Though India is the second most 
productive country in publishing papers on 
mucormycosis, it has not been adequate while 
considering the higher prevalence of mucormycosis in 
India. However, a spike in the research growth on 
mucormycosis in India was noticed in the first half of 
2021, which might be due to the outbreak of 
mucormycosis associated with the COVID-19 in 
India. The impact of research from Asian countries 
was lower than the USA and European countries. The 
lowest CPP was for research from India. 
The University of Texas was the most productive 
institute. The two Asian institutes in the top ten list 
were PGIMER and AIIMS from India; the rest were 
four each from the USA and Europe. Collaborative 
research has been actively conducted by institutions in 
the United States and Europe. Asian institutions, on 
the other hand, have produced fewer research papers 
with institutional collaboration. The number of 
research published by Asian countries with 
international cooperation was significantly lower; this 
may be the reason for less CPP of Asian publications. 
Institutions from countries other than Europe and the 
USA must involve in collaborative research for 
producing higher-quality output. 
The keyword analysis revealed that the studies on 
isavuconazole, a drug used for mucormycosis, were 
lower than the other two drugs, amphotericin B and 
posaconazole; some studies suggested higher efficacy 
of isavuconazole over amphotericin B44-45. Since the 
average year of publications of isavuconazole is 2018, 
more research is expected to be conducted on 
isavuconazole. Improvement in research on the 
surgical management of mucormycsosis is also 
required. 
The research on the diagnosis, diabetes associated 
with mucormycosis, and the mucormycosis caused by 
fatal Cunninghamella needs to be enhanced. More 
research of fungi genera Saksenaea, Lichtheimia, 
Apophysomyces, and Rhizomucor that cause 
infections in humans is required. The keywords 
related to Mucorale’s genetic studies were also very 
few, indicating that genetic studies should be given 
sufficient attention. 
 Only two countries, the USA and India, have 
published more than five hundred publications on this 
topic. As mucormycosis, a disease with a higher 
mortality rate, started to spread as a post-COVID-19 




syndrome and affected thousands of people within a 
short period4, researchers need to provide more 
attention to this disease and funding agencies should 
allocate more funding to this research field. 
Since no scientometric studies on mucormycosis 
have been published in the literature covering both 
WoS and Scopus, the findings of this study may be 
helpful to researchers in attaining a perspective of the 
current research scenario mucormycosis. Since the top 
twenty countries have published approximately 80% 
of the research output, more countries must engage in 
mucormycosis research in order to successfully tackle 
the fatal disease. 
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